Back to List View Graph View

Enhancer of zeste 2 polycomb repressive complex 2 subunit

Enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) is a catalytic component of the Polycomb repressive complex 2 (PRC2), an epigenetic regulatory complex that promotes transcriptional repression through trimethylation of histone H3 at lysine 27 (H3K27me3).

Where the papers sit

9 papers from the last 6 months study enhancer of zeste 2 polycomb repressive complex 2 subunit directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 1 human data · 7 preclinical · 1 unclassified

Themes no clear themes

Those 9 do not share a common subject.

  • EZH2 is the sole common thread across studies of cancer, sepsis-associated lung injury, gestational diabetes and inflammatory disease. Individual papers address lactylation, DNA methylation, extracellular-vesicle miR-124 delivery, mTORC1 vulnerability and EZH2/HDAC or EZH2/EGFR inhibition. The diseases, mechanisms and therapeutic strategies differ substantially, with no shared clinical endpoint or consistent direction of travel. Together, the group reflects broad exploratory interest in EZH2 rather than one coherent research question.

    9 papers

Papers

The 9 papers from the last 6 months that study enhancer of zeste 2 polycomb repressive complex 2 subunit directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

No clear themes (9)
  1. Synthesis, in silico, in vitro and in vivo evaluation of novel thiophene[3,2-b]indole-based potential EZH2 modulators as anti-inflammatory agents. Bioorganic chemistry · 29 Oct 2026 PMID 42956582
  2. EZH2 lactylation: a key epigenetic regulator and potential therapeutic target for sepsis-associated lung injury. Journal of advanced research · 27 Oct 2026 PMID 42946159
  3. Investigation of DNA methylation levels before and after treatment in breast cancer patients receiving neoadjuvant chemotherapy. Breast cancer research and treatment · 18 Oct 2026 PMID 42894051
  4. Engineered mesenchymal stem cell-derived small extracellular vesicles delivering miR-124 suppress colorectal cancer progression through EZH2 downregulation and attenuation of STAT3 signaling. Medical oncology (Northwood, London, England) · 8 Oct 2026 PMID 42848258
  5. EZH2-dependent phenotypic plasticity reveals TTP-associated and mTORC1 therapeutic vulnerabilities in lethal prostate cancer. Cell reports. Medicine · 30 Sept 2026 PMID 42815467
  6. METTL14 alleviates pyroptosis of placental trophoblasts in gestational diabetes mellitus through the lncRNA MEG8/WNT7A axis via m6A modification. Functional & integrative genomics · 11 Sept 2026 PMID 42726311
  7. Bovine Colostrum-Derived Extracellular Vesicles Impair Cancer Cell Proliferation Through Transcriptional Dysregulation. Journal of extracellular vesicles · 1 Sept 2026 PMID 42680698
  8. Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage. Molecular therapy : the journal of the American Society of Gene Therapy · 26 Aug 2026 PMID 42642931
  9. Design, synthesis and biological evaluation of EZH2/HDAC dual inhibitors for the treatment of lymphomas. European journal of medicinal chemistry · 13 Jun 2026 PMID 42288027

By study type

Human data, design not indexed (1)
  1. Investigation of DNA methylation levels before and after treatment in breast cancer patients receiving neoadjuvant chemotherapy. Breast cancer research and treatment · 18 Oct 2026 PMID 42894051
Preclinical: animal, cell and lab studies (7)
  1. Synthesis, in silico, in vitro and in vivo evaluation of novel thiophene[3,2-b]indole-based potential EZH2 modulators as anti-inflammatory agents. Bioorganic chemistry · 29 Oct 2026 PMID 42956582
  2. Engineered mesenchymal stem cell-derived small extracellular vesicles delivering miR-124 suppress colorectal cancer progression through EZH2 downregulation and attenuation of STAT3 signaling. Medical oncology (Northwood, London, England) · 8 Oct 2026 PMID 42848258
  3. EZH2-dependent phenotypic plasticity reveals TTP-associated and mTORC1 therapeutic vulnerabilities in lethal prostate cancer. Cell reports. Medicine · 30 Sept 2026 PMID 42815467
  4. METTL14 alleviates pyroptosis of placental trophoblasts in gestational diabetes mellitus through the lncRNA MEG8/WNT7A axis via m6A modification. Functional & integrative genomics · 11 Sept 2026 PMID 42726311
  5. Bovine Colostrum-Derived Extracellular Vesicles Impair Cancer Cell Proliferation Through Transcriptional Dysregulation. Journal of extracellular vesicles · 1 Sept 2026 PMID 42680698
  6. Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage. Molecular therapy : the journal of the American Society of Gene Therapy · 26 Aug 2026 PMID 42642931
  7. Design, synthesis and biological evaluation of EZH2/HDAC dual inhibitors for the treatment of lymphomas. European journal of medicinal chemistry · 13 Jun 2026 PMID 42288027
Unclassified: not yet indexed with MeSH (1)
  1. EZH2 lactylation: a key epigenetic regulator and potential therapeutic target for sepsis-associated lung injury. Journal of advanced research · 27 Oct 2026 PMID 42946159